Current Trends to Discover New Drugs Targeting Protease Inhibition

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 25 October 2025 | Viewed by 1220

Special Issue Editors


E-Mail Website
Guest Editor
Drug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraíba, João Pessoa 58070-450, PB, Brazil
Interests: molecular modeling; antitumor activity; immunomodulation; DNA binding; drug design

E-Mail Website
Guest Editor
Pharmaceutical Sciences Postgraduate Center for Biological and Health Sciences, State University of Paraíba, Av. Juvêncio Arruda, S/N, Campina Grande 58429-600, Paraíba, Brazil
Interests: drug delivery systems; hybrid materials; pharmaceutical technology; photodynamic therapy; drug discovery; antibacterial therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor Assistant
1. Laboratório de Desenvolvimento e Síntese de Fármacos, Departamento de Farmácia, Universidade Estadual da Paraíba, Campina Grande 58429-500, Brazil
2. Programa de Pós Graduação em Ciências Farmacêuticas, Universidade Estadual da Paraíba, Campina Grande 58429-500, Brazil
Interests: medicinal chemistry; molecular modeling; computer-aided drug design

Special Issue Information

Dear Colleagues,

Enzymes are biological macromolecules that have essential functions in biological processes. These functions include metabolism, absorption, digestion, and propagation, critical to maintaining homeostasis of the human organism and pathogenic microorganisms. Given their functionality, they are constantly explored as molecular drug targets. They are topics in the target-based drug design (TBDD) approach, in which small molecules are designed to target these targets, resulting in improved clinical conditions. In the current drug discovery process, proteolytic enzymes, or proteases, stand out due to their critical roles in the pathophysiology of several diseases. Several protease inhibitors exemplify the success of using these targets developed against the human immunodeficiency virus (HIV) and, more recently, Nirmatrelvir, a main protease inhibitor of the SARS-CoV-2 virus (3CLpro). Furthermore, cysteine proteases are attractive targets against neglected diseases, especially Trypanosoma cruzi (cruzain), Trypanosoma brucei (rhodesain), and Leishmaniasis (CPA, CPB, and CPC). Viral infections such as dengue and zika also present attractive proteases for the design of small protease inhibitors (NS2B-NS3). In addition, human targets such as cathepsins, TMPRSS2, and furin are the focus of drug design against several diseases. The TBDD approach is accelerated using computational computer-aided drug design (CADD) techniques, increasing the probability of finding a promising inhibitor. Thus, research groups worldwide focus on the design of small molecules targeting proteases of several diseases, providing new insight and promising hits and leads to drug development. In this context, this Special Issue will select comprehensive reviews and research papers of promising protease inhibitors designed for various diseases, including classical medicinal chemistry techniques or CADD campaigns.

Dr. Ricardo Olímpio de Moura
Dr. João Augusto Oshiro Júnior
Guest Editors

Dr. Igor José dos Santos Nascimento
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • protease inhibitors
  • target-based drug design (TBDD)
  • computer-aided drug design (CADD)
  • drug development
  • neglected diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

31 pages, 8908 KB  
Review
Exploring Subtilisin Inhibition to Discover Antimalarial Drugs: Insights into Medicinal Chemistry and Drug Discovery
by Margarida Cochicho Leonardo, Sonaly Lima Albino, Wallyson Junio Santos de Araújo, Maria Verônica de Barros Nascimento, Juan David Rodríguez-Macías, Edgar Alexander Marquez Brazon, Ricardo Olimpio de Moura, Fátima Nogueira and Igor José dos Santos Nascimento
Pharmaceuticals 2025, 18(9), 1318; https://doi.org/10.3390/ph18091318 - 3 Sep 2025
Viewed by 66
Abstract
Introduction: Malaria is a tropical disease caused by the parasite Plasmodium sp., which is considered a significant public health challenge, particularly in Africa. Among the species related to human infection, P. falciparum and P. vivax are known for their high incidence and pathogenicity. [...] Read more.
Introduction: Malaria is a tropical disease caused by the parasite Plasmodium sp., which is considered a significant public health challenge, particularly in Africa. Among the species related to human infection, P. falciparum and P. vivax are known for their high incidence and pathogenicity. Despite several approved drugs in the treatment, the increase in resistance mechanisms is becoming increasingly prevalent, which makes the discovery of effective and safer drugs challenging. Thus, it is necessary to explore new mechanisms of action for the discovery of innovative antimalarial agents. Among the explored targets, proteases, especially subtilisin, have shown great promise in the development of new therapeutic options. Method: A narrative review was conducted using the main databases to provide critical information about the subtilisin to design antimalarial drugs. Results: Critical data were found about the isoforms of subtilisins, highlighting SUB1 and SUB2. SBDD approaches were able to show that compounds designed to target the catalytic Asp372, His428, and Ser606, and other such Leu469, Gly467, and Asn520 against SUB1, presented critical results. In addition, quinoline, benzopyran, and triterpene derivatives and peptide inhibitors show their importance, and these scaffolds can be explored in further work. Conclusions: Considering the relevance of this target, this review provided insights into medicinal chemistry, the discovery of antimalarial drugs that act by inhibiting subtilisin, and promoted a promising initiative to combat malaria. Full article
(This article belongs to the Special Issue Current Trends to Discover New Drugs Targeting Protease Inhibition)
Show Figures

Graphical abstract

39 pages, 4169 KB  
Review
The SPINK Protein Family in Cancer: Emerging Roles in Tumor Progression, Therapeutic Resistance, and Precision Oncology
by Zitin Wali, Neha, Anas Shamsi, Syed Tasqeruddin and Saleha Anwar
Pharmaceuticals 2025, 18(8), 1194; https://doi.org/10.3390/ph18081194 - 13 Aug 2025
Viewed by 596
Abstract
The serine protease kazal-type inhibitor (SPINK) family is central to the regulation of proteolytic function, the establishment of physiological homeostasis, and the development of many disease states, including cancer. Emerging research has identified that members of the SPINK family are commonly overexpressed in [...] Read more.
The serine protease kazal-type inhibitor (SPINK) family is central to the regulation of proteolytic function, the establishment of physiological homeostasis, and the development of many disease states, including cancer. Emerging research has identified that members of the SPINK family are commonly overexpressed in most malignancies and are deeply implicated in pivotal oncogenic pathways like cell growth, epithelial-to-mesenchymal transition (EMT), metastasis, and drug resistance. This review provides an in-depth examination of structural and functional characteristics of SPINK proteins and their involvement in the onset and development of multiple cancers, which include prostrate, pancreatic, and colorectal carcinomas. Significantly, SPINK proteins regulate major signalling pathways, including EGFR, NF-κB, and MAPK, highlighting their role as prognostic biomarkers and therapeutic targets. The review underscores the most recent advancements in therapeutic strategies for SPINK-related pathways and outlines the bottlenecks that have restricted their use in the clinic. By integrating current evidence, this work signals the potential of SPINK proteins as good precision oncology candidates with novel options for cancer prognosis, treatment, and management. Full article
(This article belongs to the Special Issue Current Trends to Discover New Drugs Targeting Protease Inhibition)
Show Figures

Graphical abstract

Back to TopTop